Discovery of a Novel Dual Fungal CYP51/Human 5-Lipoxygenase Inhibitor: Implications for Anti-Fungal Therapy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hoobler, Eric K ^a   Rai, Ganesha ^b   Warrilow, Andrew G S ^c   Perry, Steven C ^a   Smyrniotis, Christopher J ^a   Jadhav, Ajit ^b   Simeonov, Anton ^b   Parker, Josie E ^c   Kelly, Diane E ^c   Maloney, David J ^b   Kelly, S L ^c   Holman, Theodore R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CICLOPIROX; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; KETAMINAZOLE; KETOCONAZOLE; LIPOXYGENASE INHIBITOR; OXYGENASE INHIBITOR; PF 4191834; PHENYLENEDIAMINE; SETILEUTON; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANDIDA ALBICANS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR DOCKING; NONHUMAN; NORMAL HUMAN; PROTEIN FOLDING; STRUCTURE ANALYSIS;

ANTIFUNGAL AGENTS; ARACHIDONATE 5-LIPOXYGENASE; FUNGI; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; STEROL 14-DEMETHYLASE;

OVIS;

EID: 84879493404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065928     Document Type: Article

References (61)

1. Rubin P, Mollison KW, (2007) Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 83: 188-197.
2. O'Byrne PM, Israel E, Drazen JM, (1997) Antileukotrienes in the Treatment of Asthma. Annals of Internal Medicine 127: 472-480.
3. Rådmark OP, (2000) The Molecular Biology and Regulation of 5-Lipoxygenase. American Journal of Respiratory and Critical Care Medicine 161: S11-S15.
4. Ford-Hutchinson AW, Gresser M, Young RN, (1994) 5-Lipoxygenase. Annu Rev Biochem 63: 383-417.
5. Werz O, Steinhilber D, (2006) Therapeutic options for 5-lipoxygenase inhibitors. Pharmacology & Therapeutics 112: 701-718.
6. Pergola C, Werz O, (2010) 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opinion on Therapeutic Patents 20: 355-375.
7. Zouboulis Ch C, Saborowski A, Boschnakow A, (2005) Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 210: 36-38.
8. Faergemann J, (2000) Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 1: 75-80.
9. Faergemann J, Borgers M, Degreef H, (2007) A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism. Expert Opinion on Pharmacotherapy 8: 1365-1371.
10. Borgers M, Degreef H, (2007) The role of ketoconazole in seborrheic dermatitis. Cutis 80: 359-363.
11. Scheinfeld N, (2008) Ketoconazole: a review of a workhorse antifungal molecule with a focus on new foam and gel formulations. Drugs Today (Barc) 44: 369-380.
12. Beetens JR, Loots W, Somers Y, Coene MC, de Clerck F, (1986) Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochemical Pharmacology 35: 883-891.
13. Steel HC, Tintinger GR, Theron AJ, Anderson R, (2007) Itraconazole-mediated inhibition of calcium entry into platelet-activating factor-stimulated human neutrophils is due to interference with production of leukotriene B4. Clin Exp Immunol 150: 144-150.
14. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, et al. (2008) Pirinixic Acid Derivatives as Novel Dual Inhibitors of Microsomal Prostaglandin E2 Synthase-1 and 5-Lipoxygenase. Journal of Medicinal Chemistry 51: 8068-8076.
15. McMillan RM, Walker ER, (1992) Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13: 323-330.
16. Musser JH, Kreft AF, (1992) 5-lipoxygenase: properties, pharmocology, and the quinolinyl(bridged)aryl class of inhibitors. J of Med Chem 35: 2501-2524.
17. Robinson SJ, Hoobler EK, Riener M, Loveridge ST, Tenney K, et al. (2009) Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. Journal of Natural Products 72: 1857-1863.
18. Falgueyret JP, Hutchinson JH, Riendeau D, (1993) Criteria for the identification of non-redox inhibitors of 5-lipoxygenase. Biochemical Pharmacology 45: 978-981.
19. Robert NY, (1999) Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? European Journal of Medicinal Chemistry 34: 671-685.
20. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, et al. (1991) 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256: 929-937.
21. McGill KA, Busse WW, (1996) Zileuton. The Lancet 348: 519-524.
22. Bell RL, Young PR, Albert D, Lanni C, Summers JB, et al. (1992) The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 14: 505-510.
23. Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, et al. (1997) Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. J Med Chem 40: 1955-1968.
24. Walenga RW, Showell HJ, Feinstein MB, Becker EL, (1980) Parallel inhibition of neutrophil arachidonic acid metabolism and lysosomal enzyme secretion by nordihydroguaiaretic acid. Life Sciences 27: 1047-1053.
25. Kemal C, Louis-Flamberg P, Krupinski-Olsen R, Shorter A, (1987) Reductive Inactivation of Soybean Lipoxygenase-1 by Catechols. Biochemistry 26: 7064-7072.
26. Whitman S, Gezginci M, Timmermann BN, Holman TR, (2002) Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J Med Chem 45: 2659-2661.
27. Pham C, Jankun J, Skrzypczak-Jankun E, Flowers RA, Funk MO, (1998) Structural and thermochemical characterization of lipoxygenase-catechol complexes. Biochemistry 37: 17952-17957.
28. Nelson MJ, Cowling RA, Seitz SP, (1994) Structural Characterization of Alkyl and Peroxyl Radicals in Solutions of Purple Lipoxygenase. Biochemistry 33: 4966-4973.
29. Ducharme Y, Blouin M, Brideau C, Châteauneuf A, Gareau Y, et al. (2010) The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor. ACS Medicinal Chemistry Letters 1: 170-174.
30. Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, et al. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther 334: 294-301.
31. Amagata T, Whitman S, Johnson TA, Stessman CC, Loo CP, et al. (2003) Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod 66: 230-235.
32. Deschamps JD, Gautschi JT, Whitman S, Johnson TA, Gassner NC, et al. (2007) Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorganic & Medicinal Chemistry 15: 6900-6908.
33. Vasquez-Martinez Y, Ohri RV, Kenyon V, Holman TR, Sepulveda-Boza S, (2007) Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorganic & Medicinal Chemistry 15: 7408-7425.
34. Segraves EN, Holman TR, (2003) Kinetic investigations of the rate-limiting step in human 12- and 15-lipoxygenase. Biochemistry 42: 5236-5243.
35. Rai G, Kenyon V, Jadhav A, Schultz L, Armstrong M, et al. (2010) Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. J Med Chem 53: 7392-7404.
36. Hutchinson JH, Li Y, Arruda JM, Baccei C, Bain G, et al. (2009) 5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103). Journal of Medicinal Chemistry 52: 5803-5815.
37. Fogh J, Poulsen LK, Bisgaard H, (1992) A specific asay for lukotriene B4 in human whole blood. Journal of Pharmacological and Toxicological Methods 28: 185-190.
38. Spaethe SM, Snyder DW, Pechous PA, Clarke T, VanAlstyne EL, (1992) Guinea pig whole blood 5-lipoxygenase assay: utility in the assessment of potential 5-lipoxygenase inhibitors. Biochemical Pharmacology 43: 377-382.
39. Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, et al. (2010) Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 54: 4235-4245.
40. Strushkevich N, Usanov SA, Park HW, (2010) Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol 397: 1067-1078.
41. Estabrook RW, Peterson JA, Baron J, Hildebrandt AG, (1972) The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol 2: 303-350.
42. Omura T, Sato R, (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. Ii. Solubilization, Purification, and Properties. J Biol Chem 239: 2379-2385.
43. Omura T, Sato R, (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J Biol Chem 239: 2370-2378.
44. Lamb DC, Kelly DE, Waterman MR, Stromstedt M, Rozman D, et al. (1999) Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 15: 755-763.
45. Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, et al. (2009) Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol 77: 258-268.
46. Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, et al. (2007) Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol 14: 1283-1293.
47. Lepesheva GI, Zaitseva NG, Nes WD, Zhou W, Arase M, et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B′ helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 281: 3577-3585.
48. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL, (1995) Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett 131: 337-341.
49. Lo HY, Man CC, Fleck RW, Farrow NA, Ingraham RH, et al. (2010) Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain. Bioorg Med Chem Lett 20: 6379-6383.
50. Itoh T, Nagata K, Miyazaki M, Ishikawa H, Kurihara A, et al. (2004) A selective reductive amination of aldehydes by the use of Hantzsch dihydropyridines as reductant. Tetrahedron 60: 6649-6655.
51. Ito S, Kubo T, Morita N, Ikoma T, Tero-Kubota S, et al. (2005) Azulene-Substituted Aromatic Amines. Synthesis and Amphoteric Redox Behavior of N,N-Di(6-azulenyl)-p-toluidine and N,N,N′,N′-Tetra(6-azulenyl)-p-phenylenediamine and Their Derivatives. The Journal of Organic Chemistry 70: 2285-2293.
52. Vouros P, Biemann K, (1969) The structural significance of doubly charged ion spectra. Phenylenediamine derivatives. Organic Mass Spectrometry 2: 375-386.
53. Sakurai H, Ritonga MTS, Shibatani H, Hirao T, (2005) Synthesis and Characterization of p-Phenylenediamine Derivatives Bearing an Electron-Acceptor Unit. The Journal of Organic Chemistry 70: 2754-2762.
54. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, et al. (2011) The structure of human 5-lipoxygenase. Science 331: 217-219.
55. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
56. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759.
57. Lewis ER, Johansen E, Holman TR, (1999) Large competitive kinetic isotope effects in human 15-LO catalysis measured by a novel HPLC method. J Am Chem Soc 121: 1395-1396.
58. Jefcoate CR, (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol 52: 258-279.
59. Jefcoate CR, Gaylor JL, Calabrese RL, (1969) Ligand interactions with cytochrome P-450. I. Binding of primary amines. Biochemistry 8: 3455-3463.
60. Copeland RA, (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46: 1-265.
61. Kenyon V, Rai G, Jadhav A, Schultz L, Armstrong M, et al. (2011) Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase. J Med Chem 54: 5485-5497.